Corey Davis's questions to ZFGN leadership • Q4 2015
Question
Corey Davis of Canaccord questioned the lack of a clear dose response in the trials, the potential outcomes of the FDA meeting, the projected 2016 cash burn, and whether second-generation compounds could be advanced while beloranib is on clinical hold.
Answer
CMO Dennis Kim explained the studies were not powered to show a dose difference. CEO Tom Hughes outlined various potential FDA outcomes, emphasizing the focus on the Prader-Willi syndrome (PWS) indication. CFO Patty Allen confirmed the cash guidance includes planned clinical expenses for both beloranib and the second-generation compound. Hughes added that early trials for the new compound could occur outside the U.S.